NEW YORK — Nearly 80% of patients who received a Xen gel stent with IOP-lowering topical medication after surgery experienced an IOP of less than 18 mm Hg, but early interventions were needed in 20% of patients, according to a speaker here.
“Careful follow-up is necessary at 1 month as most failures, complications and need for medications clustered around this time,” Ramesh Ayyala, MD, FRCS, FRCOphth, said at the American Glaucoma Society annual meeting.
In a longitudinal retrospective study, 211 eyes underwent Xen (Allergan) implantation. At baseline, the mean IOP for the cohort was 22 mm Hg. Qualified success was defined as an IOP of 6 mm Hg to 18 mm Hg with IOP-lowering topical medications, while absolute success was defined as an IOP of 6 mm Hg to 18 mm Hg without additional topical medications, Ayyala said.
At 6 months postoperative, less than one-fourth of eyes (22%) were deemed to be absolute successes. Additionally, Ayyala said interventions were required in nearly 20% of all eyes, with most needling and injection interventions needed in the first postoperative month. – by Robert Linnehan
Ayyala R, et al. Xen gel stent early results: Safety and efficacy in the short term. Presented at: American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.
Disclosure: Ayyala reports no relevant financial disclosures.